Option Care Health, Inc. (OPCH) Earnings Call Transcript & Summary

Good day, and welcome to the Option Care Health Second Quarter 2026 Earnings Call. [Operator Instructions]. I would now like to hand the conference over to your speaker, Mr. Bob Okunski, Vice President of Investor Relations. Please go ahead.

Good morning, and welcome to Option Care Health's Second Quarter 2026 Earnings Conference Call. With me today are John Rademacher, President and Chief Executive Officer; and Meenal Sethna, Executive Vice President and Chief Financial Officer. Before we begin, a reminder that today's discussion will include certain forward-looking statements that reflect our current assumptions and expectations. These forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from our expectations. We assume no obligation to update any forward-looking statements, except as required by law. We will also use non-GAAP financial measures when talking about the company's performance and financial condition. For more information on the specific risks and uncertainties as well as our non-GAAP measures, we encourage you to review the information in today's press release, which is posted on the Investor Relations portion of our website as well as in our Form 10-K and 10-Q filed with the SEC. Finally, for the question-and-answer portion of today's call, we ask that you limit questions to one question and one follow-up per participant. With that, I will turn the call over to John. John?

Thanks, Bob. Good morning, everyone, and thank you for joining us. We're pleased to share updates on our second quarter of 2026 today. Before I do this, I want to take a moment to say thank you to the Option Care Health team for their unwavering commitment to the patients and communities that we serve every day. I am grateful to our team members whose dedication to clinical excellence, patient outcomes, and service quality continues to differentiate Option Care Health in the marketplace. Their efforts continue to strengthen our foundation and have contributed to the positive momentum we are seeing across the business. And as recognition of the great work our team does on a daily basis, we're incredibly proud to be ranked #15 on TIME's World's Most Impactful Companies of 2026 list that was presented by TIME and Statista earlier in the second quarter. At a high level, as the nation's largest independent provider of home and alternate site infusion therapy, our strategy is built on a national scale with local responsiveness. Our comprehensive network of home infusion pharmacies and infusion suites, URAC accredited specialty pharmacy centers of excellence, along with the breadth and depth of our nursing resources uniquely positions us in the marketplace. We combine consistent high-quality clinical care with local access, leveraging our platform of infusion suites and clinics to drive clinical innovation while meeting patients where they want to be. This model not only helps us deliver reliable clinically excellent care for hospitals and health systems, specialty physician practices and health plans across the country, but also positions us as an important solution to help drive down rising health care costs. And our platform provides broad payer access, expanded pharmacy capabilities and a robust nursing network that can oversee patients in their home or one of our more than 190 facilities, making us a strong solution for pharma partners who require these services from a channel partner in support of their medicines. Turning to our results. We delivered a strong second quarter performance, reflecting the strength of our operational execution and the positive impact of our 2026 strategic initiatives and focus on recovery. Although I am pleased with our progress in the second quarter, I am not satisfied with our performance, knowing we have much greater potential given the strength of our platform and the quality of our team. In the quarter, revenue, adjusted EBITDA and EPS were all ahead of our expectations, and we had a strong quarter of cash generation. Additionally, we repurchased $150 million in stock under our buyback program in the second quarter, reinforcing our commitment to disciplined capital allocation and shareholders returns. Finally, we made significant progress on many of our strategic initiatives to position us for long-term growth. Diving into revenue dynamics within our acute therapy portfolio, we posted another strong quarter of organic growth in the high single digits as we continue to be the partner of choice for many hospitals, health systems and providers. As a reminder, acute is a very time-sensitive and local therapy platform, requiring close coordination with hospitals and health care providers to safely and effectively transition patients to home-based environment, and we do this on a national scale. Our ability to consistently deliver for providers and their patients drove another quarter of above-market high single-digit revenue growth. With acute, we saw both sequential and year-over-year growth across all key therapeutic categories and the number of patients served. Looking ahead, we expect our acute portfolio to continue to grow faster than the broader industry as we deepen our partnerships with hospitals and health systems. Across our chronic platform, revenue for the quarter was in line with last year and up high single digits sequentially from the first quarter. Breaking this down across the larger therapeutic categories we serve, we delivered another strong quarter in IG/neuro portfolio, showing sequential and year-over-year revenue growth. We remain excited about the opportunities in this portfolio and expect to continue the momentum as the key drivers for the company moving forward. Across our chronic inflammatory portfolio, as we refer to as CID, we began to stabilize our portfolio coming out of the first quarter reset and saw our second quarter patient census rise sequentially. As we move through the remainder of the year, we expect to further grow our patient census in CID products as we monitor this patient base and product mix closely. Our rare and orphan portfolio also delivered solid results for revenue growth, both sequentially and year-over-year. Growth was broad-based across a range of therapies and reflect our close relationships with our pharma partners and the strength of our clinical capabilities. We are excited about the momentum we are building and continue to focus on expanding our rare and orphan portfolio and have added new therapies to our portfolio. Some of these will not go live until late 2026, early 2027. However, this is a sign of strength of our offering. We believe we possess a competitive advantage given our national scale with local reach, broad market access for both pharmacy and medical benefits, along with consistent clinical execution through our dedicated program teams. This, combined with specialized data capture and reporting positions us as a strong partner for pharmaceutical manufacturers. We remain confident in the strength of our platform to support these clinically complex therapies and the value they provide for our patients and partners. Additionally, we have made good progress on advancing on our strategic initiatives to sharpen our execution, improve our operational competitiveness and identify the best opportunities to invest in the business to resume our growth trajectory. These initiatives include strengthening our commercial team, enhancing our go-to-market strategy and improving our operational effectiveness. Additionally, we have realigned resources and rebalanced coverage across our top specialty practices and accounts to increase reach and frequency and drive growth. Technology and data analytics also remains important enablers of our strategy as well. We are continuing to invest in artificial intelligence, digital tools, workflow automation and advanced analytics that improve care coordination, reduce administrative complexity and enhance the experience for patients, referral sources and employees. We believe these capabilities will become increasingly important as health care continues its transition towards more connected, efficient and patient-centered models of care. We are also advancing a coordinated set of technology and process improvements across a number of areas to provide a more frictionless experience for our patients and providers. These investments include developing tools in areas such as patient admission and onboarding, claims processing and patient communication. Additionally, we are deploying technology solutions incorporating artificial intelligence to improve field productivity and operational effectiveness while improving profitability. Our approach with these initiatives is to combine advanced technology with experienced teams to identify patient requirements earlier, strengthen authorization and claim submission and reduce repetitive work. Ultimately, we believe the application of artificial intelligence will reduce the cost of health care while improving clinician efficiency, enabling them to spend more time with their patients. Finally, we further expanded our ambulatory infusion clinic footprint, adding 5 new facilities in the second quarter. Utilization of these facilities continues to expand with visits growing more than 20% year-over-year. We are now operating with advanced practitioner capabilities in key markets, and we will continue to drive performance through deeper partnership with local providers. These trends reinforce our confidence in clinic-based growth as an important complement to our pharmacy model. And we continue to leverage our entire network of infusion suites, conducting over 35% of our nursing visits in one of our suites or clinics during the quarter. In closing, I want to again thank our team for their outstanding work and commitment. The strength of our second quarter results reinforces our confidence in the underlying fundamentals of the business. While we are encouraged by our progress, we are not satisfied with the results. There are still significant opportunities to improve process, enhance productivity, strengthen patient access, expand our clinical reach and drive growth. Our team is committed to continuous improvement and to delivering sustainable long-term value for our patients, partners and shareholders. And with that, I will turn the call over to Meenal. Meenal?

Thanks, John, and good morning, everyone. Our second quarter revenue was $1.4 billion, up 2% compared to last year and up 7% sequentially. We had strong execution across our acute portfolio with chronic showing strength in our IG/neuro and rare orphan platforms. As John mentioned, we were encouraged with the stabilization in our CID therapy portfolio. Gross profit dollars grew 2% sequentially with a slight decline versus last year. As a reminder, our 2026 full year revenue and gross profit projections incorporate the CID portfolio headwinds we noted last quarter. We continue to expect year-over-year revenue headwinds to be approximately 600 basis points and the gross profit headwind to be $55 million. And we continue to expect STELARA and related biosimilars will represent less than 1% of 2026 company net revenue and gross profit. SG&A declined 3% versus last year to approximately 11% of revenue, primarily driven by lower indirect labor costs and the benefits of our expense control initiatives, including a reduction in variable compensation. We continue to invest in commercial resources to support future growth. Adjusted EBITDA of $117.5 million was up 3% over last year and up 12% sequentially, reflecting our second quarter revenue growth, improved operational efficiency as well as SG&A savings. Adjusted EPS was $0.45, an increase of $0.04 over last year with an uplift of about $0.03 from the benefit of share repurchases. Our operating cash flow finished very strong in the quarter at $184 million. This was led by benefits from a number of our working capital initiatives we implemented over the last few quarters. Our balance sheet remains strong, and we ended the quarter at a net debt to leverage ratio of 2.1x. Finally, we remain committed to our current capital allocation strategy. As a reminder, our near-term capital allocation priorities start with organic investments to drive revenue growth, capacity and optimization of our cost structure. Second is return of capital to our shareholders through periodic share buybacks. During the second quarter, we repurchased $150 million of our shares, representing nearly 5% of our shares outstanding. This reduces our share repurchase authorization to $525 million. And lastly, we continue to evaluate potential acquisitions, focusing on adjacencies and tuck-ins that align with the breadth of our portfolio. Moving on to our full year forecast, our revenue guidance remains unchanged in the range of $5.675 billion to $5.775 billion. We are narrowing both our adjusted EBITDA and EPS ranges as has been our historical practice through the year. We now expect adjusted EBITDA to be in the range of $480 million to $495 million, and we expect adjusted EPS to be in the range of $1.85 to $1.92. Our EBITDA and EPS guidance reflects a number of actions we continue to take, including initiatives to drive additional revenue and gross profit growth, implementing programs to drive further reductions in our cost structure and reducing operating costs, including other cost management initiatives and variable incentive compensation. We continue to expect SG&A growth to remain at or slightly below gross profit growth for the full year 2026. Additionally, for the year, we're maintaining our estimates of net interest expense to be in the range of $50 million to $55 million and a full year tax rate range of 26% to 28% -- we are also maintaining our operating cash flow target of at least $320 million for the year. Similar to last quarter, I also wanted to provide some color on the third quarter for modeling purposes. The following assumptions are on a sequential basis, reflecting third quarter growth over the second quarter of 2026. For the third quarter, we expect sequential revenue growth in the low to mid-single digits with sequential EBITDA growth in the mid-single-digit range. We anticipate seasonality to be consistent with prior years with sequential growth through the year. And with that, I'll turn it over to the operator to open it up for questions. Operator?

And our first question will come from the line of Lisa Gill with JPMorgan. Your line is open.

I just wanted to ask a numbers question. I just want to understand 2 things. One, based on the guidance that you've given for the third quarter and I look at the margin, can you maybe just talk about the mix that you're expecting when I think about what the margin implied guidance is? And then your thoughts on cadence for the third and the fourth quarter?

Sure, Lisa. Yes, as we think about the Q3 guide, and I know there's going to be questions coming up about revenue and our progress on revenue growth. We're making some broad assumptions where, as an example, in the second quarter, we talked about high single-digit acute revenue growth. We expect that to continue as we think about the year. We're making good progress on our chronic side, and we'll talk more about our CID performance, but we're seeing patient census growth there. We expect that to continue as we progress through the year as well. And then just other initiatives that are going on around site of care and other areas as well. So I would say we would expect the revenue mix to continue, but also recognizing a bit that we'll see probably more growth coming through chronic as we continue to progress through the year.

And just as a follow-up. So is that what's driving -- if I just look at, again, the growth versus the expectation of us and the Street is stronger growth on the revenue line. And so obviously, chronic is generally more expensive of drug than we see on the chronic side, but the margins are generally a little bit lower. So is that the right way to think about it? And if I just look at kind of the midpoint of what you're talking about for each, we're talking about roughly a margin in the 8.3-ish percent range as we get into the third quarter. I just want to make sure we're thinking about this correctly as we start to see that improvement here moving into the back half of the year.

Yes. I mean I would think about that mix as we talked about. I guess I'm just trying to understand the exact question. Are you saying, is it revenue mix?

I just want to make sure we understand. Yes. Well, I just want to make sure I understand like the revenue mix and what that means to margin, right? So when I think about the adjusted EBITDA sequential growth that you're talking about. So again, if we use that 5% is the midpoint of a mid-single-digit number, and we use the midpoint of 3% growth on revenue, that's going to put the margin on EBITDA somewhere in the range of 8.3%. I just want to make sure that we're thinking about that correctly, and there's not something else that we need to consider. And how we think about all of the initiatives that you have, et cetera, right, on that margin impact. And again, the mix to what I talked about chronic versus acute. I just -- again, I just want to make sure we have this correct.

Sure. No, that makes sense, and thanks for the clarification. Yes, the assumptions and how you're thinking about it makes sense, I would say that's pretty reasonable and in line with how we're thinking about our guidance for the third quarter.

One moment for our next question. That will come from the line of David MacDonald with Truist. Your line is open.

John, I just had a quick question. I mean on the first quarter call, you laid out a handful of different initiatives broadening the specialty call points, expanding the commercial team, realigning resources. You touched on a couple of them in your prepared remarks. I'm just curious if you can kind of give us a little bit of an update in terms of -- since you guys have put those in place, and I realize it's early, are there a couple of those that are gaining traction pretty quickly? Which ones should we think about being more on the come as we get through 2026 into 2027? Just any additional perspective on some of those initiatives and the timing of impacts would be helpful.

Yes. Dave, thanks for the question. Very good progress on the reset that we had identified within the commercial team and realigning those resources. In my prepared remarks, I did call out we realigned the resources around the call points. We look to expand reach and frequency. We have put additional resources in place as well as realigned some of those resources. within the markets that they serve. And I'd say that is indicative of some of the comments around, number one, the stabilization of the CID census and beginning to grow again in the second quarter, the strength of what we saw within our IG/neuro portfolio and again, the capture of the market demand by reaching into those call points. So the reach and frequency continues to improve from that standpoint. And the ability for us to deploy some technology that helps us better target our activities was also deployed. As you called out, these things take time, and we expect that it will continue to build as we go through the back half of the year and continue into 2027. But I'm pleased with the progress that the team is making. I know there's a lot more opportunity that sits before us as we drive that forward. But that commercial go-to-market strategy and the alignment of the commercial resources, I'd say we made significant headways in the quarter of setting the right framework and putting some of the pieces in place to drive that growth as we move forward. The only other thing I'd tell you, Dave, is we did make significant progress in the deployment of some of the advanced technology and artificial intelligence within the portfolio. As we have called out before, a lot of that sits in back-office capabilities, but things that help support nursing optimization and getting our nurses more productive and efficient by route optimizing and looking at scheduling on that. We look at things around deliveries and optimizing the delivery and the path that we utilize for that. We're deploying the technology to really help our patient registration and onboarding aspect. And again, really solid progress in either deploying some of that technology into test markets and expanding from there or deploying it broadly as part of enhancements that we put into our base technology solutions. So good progress there, and I think you saw that in the results in the second quarter, and we expect that's going to continue to build momentum as we move through the back half of the year and then continue with our focus in driving growth over the near and long term.

Okay. And then just my quick follow-up. Look, John, I know you mentioned still work to be done. But as we think about STELARA and that kind of finally being put to bed and just some of the momentum that you're going to build throughout the year, not asking you to comment on '27, but how do you think about just getting back to a more normalized cadence relative to the long-term growth algorithm and just how we should think about that?

Yes. We are putting the pieces in place right now to drive the performance of the organization. As I said in my comments, good progress. We knew coming out of the reset in the first quarter, we need to be building on that and feel as if we're making progress against that and continue to push that as we move through the second half of the year. As you would expect, we'll be a little bit elusive. We're not prepared to give '27 guidance on that. But we like the building momentum that we have. We like the build that you see in the back half of the year as we're looking quarter after quarter. And our belief is that we're putting the right pieces in place. There's still more work to do. The team is focused around continuous improvement, and we will be driving that as we move forward. But we like the pace, and we think that we can continue to push on the sequential growth and getting back towards the growth view that we've had in this organization and being able to be the partner of choice with our referral sources and being able to continue to expand our patient census as we move forward.

One moment for our next question, and that will come from the line of Brian Tanquilut with Jefferies.

Meenal, when I think of the guidance that you've given here, especially with Q3, it looks like there's a step-up implied in Q4 that's sort of in the 11% to 19% quarter-over-quarter range. Just curious what drives that when considering last year, that number was like 7% ex procurement. So just curious how you're thinking about the sequential drivers here more from Q3 to Q4 than the Q2 to Q3 ramp.

Sure. Yes. So on the Q3 to Q4, and I'm not going to quote specific numbers because I'm sure everybody has got their own consensus out there on what they think Q4 looks like. But in general, if you take a look at some history beyond just last year, but going back a few years, we've seen, one, that half 2, the second half of the year versus first half of the year, there's been somewhere around high single-digit, low double-digit growth rate that's out there. And even if you just look at percent of what's achieved, it tends to be a little bit -- the EBITDA tends to be a little bit lower in the first half of the year as a percentage of the full year versus half 2. So that sequential growth has been there, and it's more of an expectation as we think about it. Maybe I'll just add on what are some of the specific drivers that we think about for the second half. John talked a lot about just the building momentum that we have around revenue, which includes the commercial resources. We talked about the fact that we had been investing in more commercial resources starting late last year into the beginning part of this year, and we expect the -- I'll call it, the increased productivity as these resources ramp up. And so that's going to be a positive to revenue that, that drops through. As part of that also just our chronic census recovery, right? We started that build in the second quarter. We expect that to continue in the third and fourth quarter. So you've got that sequence going as well. And some of that is also cost initiatives. And I want to point out, it's not just a onetime cost reduction. You're always looking at that as part of a broader portfolio and how you operate the company. But at the same time, John just mentioned some of the deployment that we've done around technology, some AI pieces. We are in the process of -- in some cases, we just started deploying it in the first half of the year, more to go in the back half. So that's part of that ramp. So -- and then just a number of things we talked around our normal procurement initiatives that we're going after, we continue to work with payers around value realization and site of care programs. So it's a broad basket of things. But again, we expect continued progressive improvement to the year. That's how we're thinking about with the guidance that we put forward in Q3, but then continued momentum into Q4 as well.

Got it. And then maybe, John, just as I think about the market backdrop here, I mean, obviously, you're gaining strength continuously in acute. If you can just walk me through how you're thinking about what's going on in the competitive dynamics of infusion, number one. And then just curious what you're seeing in terms of the formulary changes that have occurred in the market, including the CVS changes, I think it was midyear.

Yes. Again, it's always been a competitive market, and we do feel that we're well positioned with the capability set that we have and this national scale that has local responsiveness. The dynamics continue to be strong, as you know, Brian, in the marketplace, but we are making progress against that and continue to invest in what we believe are the right areas to continue on our growth and continue to be a partner of choice and capture that market demand. And it starts with the breadth of our portfolio, as you called out, the ability that we have to be able to serve hospitals, health systems with our solutions team on that end, our continued to build within the specialty practices, the clinics and then our focus around manufacturer programs that support limited distribution drugs as well as rare and orphan. All of that, we think, continues to really demonstrate the breadth of our capabilities, utilizes our clinical resources to their fullest and capitalizes on a unique platform that we have that has national scale in that local responsiveness. So I feel like we're well positioned. We don't underestimate the competitive dynamics. We know that we've got to win every single day. That's kind of the rally cry for the team into the marketplace is to be that partner of choice and capture that market demand. But we really believe that the breadth of our portfolio and the partnerships that we're developing with key referral sources and within the health care providers within the markets that we serve that we're very well positioned to continue to grow and to continue to capture market demand.

And that will come from the line of Scott Fidel with Goldman Sachs.

You have Valentine [ Vlasov ] on for Scott Fidel. Earlier this month, CMS proposed expanding Medicare coverage for certain home infusion pumps and drugs beginning in 2027. How do you think about the potential impact of that proposal, would be helpful.

Yes. As we have said in previous calls, we continue to be active in Washington, both in the support of the NHIA, the National Home Infusion Association and their activities to expand coverage to Medicare beneficiaries as well as activities that we take on as an independent company within that marketplace. What had been proposed and what is moving forward is a very narrow set of therapies and therapeutic categories that will, again, receive coverage in an expanded basis within Medicare. We think we're well positioned to participate in that and support that expansion in the marketplace. I don't believe it's going to be a significant material aspect given the limited therapies that are combined there. But any opportunity that there is to expand market access, any opportunity that there is to demonstrate to CMS the value of being able to treat patients safely in the home and in site of care that reduces the total cost, we think, is a positive aspect and one that we'll continue to build on in the way that we're engaging in Washington and helping to provide additional insights around the value that can be derived and the cost savings that could be generated if CMS were to expand access to the home and to alternate site infusion therapy.

Our next question will come from the line of Erin Wright with Morgan Stanley.

How much of the guide at this point is reliant on underlying kind of proactive administrative cost cuts? And can you talk about what's in your control on that front as we go into the second half and how to think about some of those moving pieces as we go into 2027, like what's the right jumping off point? And then also just from a capital deployment standpoint, I just want to make sure like future buybacks are not embedded in your current guidance, right, at least outside of what has been announced so far? Or can you speak on kind of the buyback opportunity, too?

Yes. Thanks, Erin. So maybe just answering the second question first. Our current guidance does not include any new or prospective buybacks. It only incorporates the buyback that we did, the $150 million buyback that we did as part of the second quarter. So nothing incremental is assumed in there. As to the assumptions for the guidance as we think about Q3 and Q4, look, we've got -- and I think as I talked about this just on a previous question, we have a number of things that we're working on a number of initiatives. I would not put cost reductions like G&A cost reductions as the top driver of how we're getting to our guide. I would start with commercial, both revenue growth, the positive impact from the investments that we're making with our commercial resources starting from late last year and seeing progressive improvement, and we started to see that in the second quarter. The continued improvement in our CID census with the first quarter being the base, et cetera. So I'd use that as the first piece of the foundation. But then along the way, as we normally do, there will be a number of, I'll say, whether it's GP or SG&A things that we're going after. It's not necessarily cost cuts just to cut, but it may be, again, as we talked about, technology deployment that we're doing that overall requires fewer resources or the resources that we have, as an example, in nursing become more productive if they're able to spend more time with patients as opposed to some other less productive activities, et cetera. And just some of the other technology deployment we talked about with patient registration and patient administration, those sorts of things. Again, everything we can do to make it a more paperless, frictionless experience where we think about the perfect claim as an example, that also improves our cost position and it doesn't necessarily require just standard cuts. So we've got a lot of things that we're going after, and I feel good about the progress that we're making and what's in the hopper.

One moment for our next question. That will come from the line of Philip Chickering with Deutsche Bank. Your line is open.